Literature DB >> 20624009

Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?

Thomas Gremmel1, Andreas Calatzis, Sabine Steiner, Alexandra Kaider, Daniela Seidinger, Renate Koppensteiner, Christoph W Kopp, Simon Panzer.   

Abstract

Adenosine 5′-diphosphate (ADP) inducible aggregation is used to assess platelet response to thienopyridines. Thrombin receptor-activating peptide-6 (TRAP-6) inducible aggregation may serve as a positive control because it acts via the thrombin receptor protease-activating receptor-1, which is not blocked by thienopyridines. We therefore investigated if TRAP-6 is suitable as a positive control when assessing residual platelet reactivity to ADP. Platelet response to clopidogrel was assessed in 200 patients on dual antiplatelet therapy using ADP inducible platelet aggregation by light transmission aggregometry (LTA), multiple electrode aggregometry (MEA), and the shear-dependent Impact-R. Test specificities were monitored by TRAP-6 inducible platelet aggregation. The aggregation-independent vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay served for comparisons. ADP inducible aggregation was correlated to that by TRAP-6 (r = 0.33 to 0.72; p < 0.001 for all assays). A linear correlation was seen within MEA (r = 0.72). LTA TRAP-6 correlated weakly with the VASP assay (r = 0.19; p = 0.01), while there were no correlations of TRAP-6 responses by MEA or the Impact-R with the VASP assay (r = 0.03 and &#x2212;0.09; p > 0.05). In all three assays, differences between ADP and TRAP-6 inducible aggregation varied considerably. Within MEA, TRAP-6 inducible aggregation was almost always stronger than ADP inducible aggregation, while within LTA and the Impact-R, weak responses to ADP were associated with both, weak and strong responses to TRAP-6. In conclusion, the application of TRAP-6 as a positive control for platelet reactivity has major limitations and results need to be cautiously interpreted on an individual basis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624009     DOI: 10.3109/09537104.2010.493587

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  8 in total

1.  A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.

Authors:  Christoph B Olivier; Katharina Schnabel; Christoph Brandt; Patrick Weik; Manfred Olschewski; Qian Zhou; Christoph Bode; Philipp Diehl; Martin Moser
Journal:  Clin Res Cardiol       Date:  2014-07-16       Impact factor: 5.460

2.  Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.

Authors:  Rolf P Kreutz; Jeffrey A Breall; Yvonne Kreutz; Janelle Owens; Deshun Lu; Islam Bolad; Elisabeth von der Lohe; Anjan Sinha; David A Flockhart
Journal:  Thromb Res       Date:  2012-03-28       Impact factor: 3.944

3.  High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting.

Authors:  Jonathan Rilinger; Melanie Meyer; Katharina Schnabel; Patrick Weik; Anne Charlet; Jennifer S Esser; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl; Christoph B Olivier
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

4.  Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors.

Authors:  Patricia P Wadowski; Joseph Pultar; Constantin Weikert; Beate Eichelberger; Benjamin Panzer; Kurt Huber; Irene M Lang; Renate Koppensteiner; Simon Panzer; Thomas Gremmel
Journal:  Res Pract Thromb Haemost       Date:  2019-05-22

5.  A Prospective Observational Study on Multiplate®-, ROTEM®- and Thrombin Generation Examinations Before and Early After Implantation of a Left Ventricular Assist Device (LVAD).

Authors:  Philipp Opfermann; Alessia Felli; Christine Schlömmer; Martin Dworschak; Michele Bevilacqua; Mohamed Mouhieddine; Daniel Zimpfer; Andreas Zuckermann; Barbara Steinlechner
Journal:  Front Med (Lausanne)       Date:  2022-02-25

6.  The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count.

Authors:  Christoph B Olivier; Melanie Meyer; Hans Bauer; Katharina Schnabel; Patrick Weik; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

7.  Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients.

Authors:  Sascha Marx; Maximilian Splittstöhser; Frederik Kinnen; Eileen Moritz; Christy Joseph; Sebastian Paul; Heiko Paland; Carolin Seifert; Madlen Marx; Andreas Böhm; Edzard Schwedhelm; Kerstin Holzer; Stephan Singer; Christoph A Ritter; Sandra Bien-Möller; Henry W S Schroeder; Bernhard H Rauch
Journal:  Oncotarget       Date:  2018-05-25

8.  Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors.

Authors:  Patricia P Wadowski; Joseph Pultar; Constantin Weikert; Beate Eichelberger; Irene M Lang; Renate Koppensteiner; Simon Panzer; Thomas Gremmel
Journal:  J Cardiovasc Pharmacol Ther       Date:  2020-10-27       Impact factor: 2.457

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.